Anatomy of a Target – PrEP

In Px Wire, our quarterly newsletter, we looked at the strengths and limitations of new PEPFAR targets, new UNAIDS targets, new guidelines on ART and PrEP from the WHO and new Sustainable Development Goals.

In this excerpt from our centerspread graphic, we take a closer look at PrEP.

Anatomy of a Target – Treatment

In Px Wire, our quarterly newsletter, we looked at the strengths and limitations of new PEPFAR targets, new UNAIDS targets, new guidelines on ART and PrEP from the WHO and new Sustainable Development Goals.

In this excerpt from our centerspread graphic, we take a closer look at antiretroviral therapy and treatment.

Px Wire October-December 2015, Vol. 8, No. 4

In this issue of Px Wire, our quarterly newsletter, we decipher the strengths and limitations of the multiple recent developments impacting HIV prevention: new PEPFAR targets, new UNAIDS targets, new guidelines on ART and PrEP from the WHO and new Sustainable Development Goals. What does each development mean, and how do advocates tailor their advocacy accordingly?

Global Investment in HIV Cure Research and Development 2014

Now in its third year, this annual report, a collaboration between AVAC and the International AIDS Society Towards a Cure Initiative, analyzes global investment in HIV cure research.

Implementing Comprehensive HIV and STI Programs with Men Who Have Sex With Men: Practical Guidance for Collaborative Interventions

The United Nations Population Fund (UNFPA) and the Global Forum on MSM & HIV (MSMGF) have created this tool for implementing comprehensive sexual health services for men who have sex with men (MSM). Working together with UNDP, WHO, USAID, PEPFAR and over 100 experts from around the world, this publication targets public health officials and program managers, as well as NGOs and health workers implementing HIV and STI programs with MSM.

Prevention Now: An Integration Agenda For Women, By Women

The Prevention Now report is the product of a meeting convened by CHANGE and AVAC in June 2015 in Nairobi. Advocates from across sub-Saharan Africa and the US leading advocacy efforts on sexual and reproductive health and rights, HIV prevention and treatment, gender based violence, sex worker rights, youth health and rights, maternal health and abortion access organizations came together to develop an advocacy agenda around integration.

Oral Pre-Exposure Prophylaxis – Putting a new choice in context

The World Health Organization (WHO) released updated guidance in late 2015 on oral pre-exposure prophylaxis (PrEP), containing tenofovir (TDF), as an additional HIV prevention choice. The new guidance is significantly broader than previously and creates real opportunities to move forward with implementing PrEP as part of comprehensive HIV programmes.

This publication, produced collaboratively between UNAIDS, WHO and AVAC, is intended to complement WHO recommendations and support the optimal use of oral PrEP to protect individuals and contribute to ending the AIDS epidemic.

HIV Prevention Research & Development Funding Trends, 2000-2014: Investing in innovation in an evolving global health and development landscape

This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. In 2014, the reported funding for HIV prevention R&D decreased by US$10 million from the previous year to a total of US$1.25 billion. While investments toward research in preventive vaccines, PrEP, female condoms and prevention of vertical transmission increased in 2014, investments towards microbicides, treatment as prevention and medical male circumcision decreased.

Overall funding has remained at nearly the same level for approximately a decade. As in past years, the public sector made up the majority of total funding at US$990 million (79 percent), with the US public sector contributing US$868 million (69 percent). European public-sector funding made up US$69 million (five percent), public-sector investment from other countries made up US$52 million (four percent), philanthropic investment was US$200 million (16 percent) and investment from the commercial sector was US$63 million (five percent).

A one-page summary document is also available.

HIV Prevention Research & Development Funding Trends, 2000-2014: Investing in innovation in an evolving global health and development landscape (1-pager)

This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. In 2014, the reported funding for HIV prevention R&D decreased by US$10 million from the previous year to a total of US$1.25 billion. While investments toward research in preventive vaccines, PrEP, female condoms and prevention of vertical transmission increased in 2014, investments towards microbicides, treatment as prevention and medical male circumcision decreased.

Overall funding has remained at nearly the same level for approximately a decade. As in past years, the public sector made up the majority of total funding at US$990 million (79 percent), with the US public sector contributing US$868 million (69 percent). European public-sector funding made up US$69 million (five percent), public-sector investment from other countries made up US$52 million (four percent), philanthropic investment was US$200 million (16 percent) and investment from the commercial sector was US$63 million (five percent).

Px Wire July-September 2015, Vol. 8, No. 3

Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy.

In this issue, we describe the calls to expand ART access to all who need it, which have been amplified over the two months since the results of the START trial. We also document a growing demand for PrEP and the need for updated guidance from the WHO and targets from UNAIDS. And we look at the increasing role civil society is playing at developing PEPFAR Country Operating Plans (COPs) which guide targets, geography, interventions and budget levels on an annual basis.

In our centerspread, we look backwards and forward, at the conferences that took place in Vancouver and Durban in 1996 and 2000 and will again this year and the next.

This issue is also available as a webpage.